Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARFGEF2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARFGEF2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARFGEF2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARFGEF2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARFGEF2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ARFGEF2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARFGEF2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARFGEF2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005105613 | Prostate | Tumor | regulation of small GTPase mediated signal transduction | 80/3246 | 302/18723 | 3.96e-05 | 4.57e-04 | 80 |
GO:000689213 | Prostate | Tumor | post-Golgi vesicle-mediated transport | 35/3246 | 104/18723 | 4.14e-05 | 4.70e-04 | 35 |
GO:009887613 | Prostate | Tumor | vesicle-mediated transport to the plasma membrane | 42/3246 | 136/18723 | 7.47e-05 | 7.84e-04 | 42 |
GO:004657814 | Prostate | Tumor | regulation of Ras protein signal transduction | 53/3246 | 189/18723 | 1.63e-04 | 1.46e-03 | 53 |
GO:000181914 | Prostate | Tumor | positive regulation of cytokine production | 109/3246 | 467/18723 | 4.98e-04 | 3.67e-03 | 109 |
GO:000703212 | Prostate | Tumor | endosome organization | 26/3246 | 82/18723 | 1.07e-03 | 6.87e-03 | 26 |
GO:000689313 | Prostate | Tumor | Golgi to plasma membrane transport | 19/3246 | 60/18723 | 4.84e-03 | 2.37e-02 | 19 |
GO:00326408 | Prostate | Tumor | tumor necrosis factor production | 44/3246 | 181/18723 | 1.05e-02 | 4.38e-02 | 44 |
GO:00326808 | Prostate | Tumor | regulation of tumor necrosis factor production | 44/3246 | 181/18723 | 1.05e-02 | 4.38e-02 | 44 |
GO:00717068 | Prostate | Tumor | tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:19035558 | Prostate | Tumor | regulation of tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
GO:001605017 | Thyroid | PTC | vesicle organization | 163/5968 | 300/18723 | 4.74e-16 | 3.69e-14 | 163 |
GO:000689218 | Thyroid | PTC | post-Golgi vesicle-mediated transport | 66/5968 | 104/18723 | 3.36e-11 | 1.24e-09 | 66 |
GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
GO:000689317 | Thyroid | PTC | Golgi to plasma membrane transport | 41/5968 | 60/18723 | 7.26e-09 | 1.82e-07 | 41 |
GO:009887618 | Thyroid | PTC | vesicle-mediated transport to the plasma membrane | 74/5968 | 136/18723 | 4.20e-08 | 9.08e-07 | 74 |
GO:000703210 | Thyroid | PTC | endosome organization | 48/5968 | 82/18723 | 5.65e-07 | 9.04e-06 | 48 |
GO:005105617 | Thyroid | PTC | regulation of small GTPase mediated signal transduction | 132/5968 | 302/18723 | 9.26e-06 | 1.04e-04 | 132 |
GO:004657817 | Thyroid | PTC | regulation of Ras protein signal transduction | 88/5968 | 189/18723 | 1.62e-05 | 1.70e-04 | 88 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARFGEF2 | SNV | Missense_Mutation | | c.1962N>G | p.Phe654Leu | p.F654L | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.2026N>A | p.Glu676Lys | p.E676K | Q9Y6D5 | protein_coding | tolerated(0.23) | benign(0.391) | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.817N>A | p.Glu273Lys | p.E273K | Q9Y6D5 | protein_coding | tolerated(0.46) | benign(0.014) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.2851N>C | p.Phe951Leu | p.F951L | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A1IL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARFGEF2 | SNV | Missense_Mutation | novel | c.1595N>A | p.Arg532His | p.R532H | Q9Y6D5 | protein_coding | tolerated(0.15) | probably_damaging(0.986) | TCGA-E9-A54Y-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.3508G>A | p.Glu1170Lys | p.E1170K | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ARFGEF2 | insertion | In_Frame_Ins | novel | c.1886_1887insAAACCCCACTTCTACTAAAAA | p.Thr629_Val630insAsnProThrSerThrLysAsn | p.T629_V630insNPTSTKN | Q9Y6D5 | protein_coding | | | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.3959_3960insCGTGTTGTAAGCGCTTGATGAGTATTAATCT | p.Gly1321ValfsTer3 | p.G1321Vfs*3 | Q9Y6D5 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.4621_4622insTCCCAAAACACTGAAATAGGGTGAAAA | p.Ala1541delinsValProLysHisTerAsnArgValLysThr | p.A1541delinsVPKH*NRVKT | Q9Y6D5 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.2502_2503insTTTTAGTCATCTTTATAT | p.Glu834_Leu835insPheTerSerSerLeuTyr | p.E834_L835insF*SSLY | Q9Y6D5 | protein_coding | | | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |